Incyte | INCY - Umlaufvermögen

Aktienkurs
98.60
Täglich Wechseln
-0.50 -0.50%
Monatlich
4.76%
Jährlich
58.96%
Q2 Prognose
92.62




Umlaufvermögen Veränderung Datum
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agenus USD 133.44M 514K 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 29.39B 6.24B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Exelixis USD 1.44B 41.03M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12